Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Pain and Therapy

Open Access 24-09-2024 | Tramadol | ORIGINAL RESEARCH

Safety of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: Pooled Analysis of Three Phase 3 Randomized Trials

Authors: Eugene R. Viscusi, Richard Langford, Adelaida Morte, Anna Vaqué, Jesús Cebrecos, Mariano Sust, José María Giménez-Arnau, Oscar de Leon-Casasola

Published in: Pain and Therapy

Login to get access

Abstract

Introduction

Multi-modal analgesia is desirable for the management of acute pain since it can provide effective pain relief at lower doses, thereby aiding tolerability. Co-crystal of tramadol-celecoxib (CTC) provides effective analgesia in models of acute pain. Co-crystallization can alter the pharmacokinetics of individual components, potentially improving tolerability. We sought to better understand the safety and tolerability of CTC in patients with acute postoperative pain.

Methods

We conducted a pooled analysis of safety data from three phase 3 randomized controlled trials in adults with acute moderate-to-severe pain following oral surgery, bunionectomy, and elective abdominal hysterectomy. We present data for CTC 200 mg twice daily (BID) and its comparators: tramadol 50 mg four times daily (QID) (one trial), tramadol 100 mg QID (two trials), celecoxib 100 mg BID (two trials), and placebo (three trials).

Results

In total, n = 551 patients received CTC 200 mg BID, n = 183 received tramadol 50 mg QID, n = 368 received tramadol 100 mg QID, n = 388 received celecoxib 100 mg BID, and n = 274 received placebo. The prevalence of adverse events (AEs) related to study drug up to 48 h was numerically lower with CTC 200 mg BID (35.9%) than with tramadol 50 mg QID (47.5%) and 100 mg QID (44.8%) but greater than with celecoxib 100 mg BID (12.4%) and placebo (20.4%). The most frequent AEs related to study drug up to 48 h were somnolence, nausea, dizziness, and vomiting, which occurred more frequently in patients receiving tramadol 100 mg QID than in those receiving CTC 200 mg BID.

Conclusion

CTC 200 mg BID appears to be better tolerated than tramadol 100 mg QID, possibly because of reduced total exposure to tramadol. This may contribute to a more favorable benefit-risk profile for CTC versus individual components, making it a promising treatment for acute pain.

Trial Registration

ClinicalTrials.gov identifiers: NCT03108482, NCT02982161 (EudraCT: 2016-000592-24), NCT03062644 (EudraCT: 2016-000593-38).
Appendix
Available only for authorised users
Literature
1.
Meissner W, Coluzzi F, Fletcher D, et al. Improving the management of post-operative acute pain: priorities for change. Curr Med Res Opin. 2015;31(11):2131–43.CrossRefPubMed
2.
3.
Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003;97(2):534–40.CrossRefPubMed
4.
Todd KH, Ducharme J, Choiniere M, et al. Pain in the emergency department: results of the pain and emergency medicine initiative (PEMI) multicenter study. J Pain. 2007;8(6):460–6.CrossRefPubMed
5.
Mura P, Serra E, Marinangeli F, et al. Prospective study on prevalence, intensity, type, and therapy of acute pain in a second-level urban emergency department. J Pain Res. 2017;10:2781–8.CrossRefPubMedPubMedCentral
6.
Butti L, Bierti O, Lanfrit R, et al. Evaluation of the effectiveness and efficiency of the triage emergency department nursing protocol for the management of pain. J Pain Res. 2017;10:2479–88.CrossRefPubMedPubMedCentral
7.
Gan TJ, Epstein RS, Leone-Perkins ML, Salimi T, Iqbal SU, Whang PG. Practice patterns and treatment challenges in acute postoperative pain management: a survey of practicing physicians. Pain Ther. 2018;7(2):205–16.CrossRefPubMedPubMedCentral
8.
9.
Stegmann JU, Weber H, Steup A, Okamoto A, Upmalis D, Daniels S. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr Med Res Opin. 2008;24(11):3185–96.CrossRefPubMed
10.
Singla NK, Pollak R, Gottlieb I, et al. Efficacy and safety of intravenously administered tramadol in patients with moderate to severe pain following bunionectomy: a randomized, double-blind, placebo-controlled, dose-finding study. Pain Ther. 2020;9(2):545–62.CrossRefPubMedPubMedCentral
11.
Oderda G. Challenges in the management of acute postsurgical pain. Pharmacotherapy. 2012;32(9 Suppl):6S-11S.PubMed
12.
Oderda GM, Said Q, Evans RS, et al. Opioid-related adverse drug events in surgical hospitalizations: impact on costs and length of stay. Ann Pharmacother. 2007;41(3):400–6.CrossRefPubMed
13.
Gupta K, Nagappa M, Prasad A, et al. Risk factors for opioid-induced respiratory depression in surgical patients: a systematic review and meta-analyses. BMJ Open. 2018;8(12):e024086.CrossRefPubMedPubMedCentral
14.
Dunn KE, Bergeria CL, Huhn AS, Strain EC. A systematic review of laboratory evidence for the abuse potential of tramadol in humans. Front Psychiatry. 2019;10:704.CrossRefPubMedPubMedCentral
15.
Reines SA, Goldmann B, Harnett M, Lu L. Misuse of tramadol in the United States: an analysis of the National Survey of Drug Use and Health 2002–2017. Subst Abuse. 2020;14:1178221820930006.PubMedPubMedCentral
16.
Edinoff AN, Kaplan LA, Khan S, et al. Full opioid agonists and tramadol: pharmacological and clinical considerations. Anesth Pain Med. 2021;11(4):e119156.CrossRefPubMedPubMedCentral
17.
Marsch LA, Bickel WK, Badger GJ, et al. Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans. J Pharmacol Exp Ther. 2001;299(3):1056–65.PubMed
18.
Almansa C, Mercè R, Tesson N, Farran J, Tomàs J, Plata-Salamán CR. Co-crystal of tramadol hydrochloride–celecoxib (ctc): a novel API–API co-crystal for the treatment of pain. Cryst Growth Des. 2017;17(4):1884–92.CrossRef
19.
20.
21.
Videla S, Lahjou M, Vaqué A, et al. Single-dose pharmacokinetics of co-crystal of tramadol-celecoxib: results of a four-way randomized open-label phase I clinical trial in healthy subjects. Br J Clin Pharmacol. 2017;83(12):2718–28.CrossRefPubMedPubMedCentral
22.
Videla S, Lahjou M, Vaqué A, et al. Pharmacokinetics of multiple doses of co-crystal of tramadol-celecoxib: findings from a four-way randomized open-label phase I clinical trial. Br J Clin Pharmacol. 2018;84(1):64–78.CrossRefPubMed
23.
Port A, Almansa C, Enrech R, Bordas M, Plata-Salamán CR. Differential solution behavior of the new API–API co-crystal of tramadol–celecoxib (CTC) versus its constituents and their combination. Cryst Growth Des. 2019;19(6):3172–82.CrossRef
24.
Cebrecos J, Carlson JD, Encina G, et al. Celecoxib-tramadol co-crystal: a randomized 4-way crossover comparative bioavailability study. Clin Ther. 2021;43(6):1051–65.CrossRefPubMed
25.
Viscusi ER, de Leon-Casasola O, Cebrecos J, et al. Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: a phase 3, randomized, double-blind, factorial, active- and placebo-controlled trial. Pain Pract. 2023;23(1):8–22.CrossRefPubMed
26.
Langford R, Pogatzki-Zahn EM, Morte A, et al. Co-crystal of tramadol-celecoxib versus tramadol or placebo for acute moderate-to-severe pain after oral surgery: randomized, double-blind, phase 3 trial (STARDOM1). Adv Ther. 2024;41(3):1025–45.CrossRefPubMedPubMedCentral
27.
Langford R, Morte A, Sust M, et al. Efficacy and safety of co-crystal of tramadol-celecoxib (CTC) in acute moderate-to-severe pain after abdominal hysterectomy: a randomized, double-blind, phase 3 trial (STARDOM2). Eur J Pain. 2022;26(10):2083–96.CrossRefPubMedPubMedCentral
28.
Langford R, Margarit C, Morte A, et al. Co-crystal of tramadol-celecoxib (CTC) for acute moderate-to-severe pain. Curr Med Res Opin. 2024;40(3):455–68.CrossRefPubMed
29.
Kim S, Song IA, Lee B, Oh TK. Risk factors for discontinuation of intravenous patient-controlled analgesia after general surgery: a retrospective cohort study. Sci Rep. 2023;13(1):18318.CrossRefPubMedPubMedCentral
30.
Macintyre PE. Safety and efficacy of patient-controlled analgesia. Br J Anaesth. 2001;87(1):36–46.CrossRefPubMed
31.
Grovle L, Hasvik E, Haugen AJ. Rescue and concomitant analgesics in placebo-controlled trials of pharmacotherapy for neuropathic pain and low back pain. Pain. 2020;161(1):3–10.CrossRefPubMed
32.
33.
34.
35.
Cooper SA, Desjardins PJ, Turk DC, et al. Research design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendations. Pain. 2016;157(2):288–301.CrossRefPubMed
36.
Viscusi ER, de Leon-Casasola O, Cebrecos J, et al. Abstract no. 435: Celecoxib-tramadol co-crystal in patients with moderate-to-severe pain following bunionectomy with osteotomy: secondary analyses of a phase 3, randomised, double-blind, factorial, active-and placebo-controlled trial (p. 175). Abstract book: 12th congress of the European Pain Federation (EFIC). 2022. https://​efic-congress.​org/​wp-content/​uploads/​2022/​04/​ABSTRACT-BOOK-2022.​pdf. Accessed May 5, 2024.
Metadata
Title
Safety of Co-Crystal of Tramadol-Celecoxib (CTC) in Patients with Acute Moderate-to-Severe Pain: Pooled Analysis of Three Phase 3 Randomized Trials
Authors
Eugene R. Viscusi
Richard Langford
Adelaida Morte
Anna Vaqué
Jesús Cebrecos
Mariano Sust
José María Giménez-Arnau
Oscar de Leon-Casasola
Publication date
24-09-2024
Publisher
Springer Healthcare
Published in
Pain and Therapy
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-024-00655-w

2024 ESC Congress

Noise pollution dangerous for heart health

Two studies underscore the adverse impact of noise pollution on the risk for and prognosis after myocardial infarction.

Read more

Post-TAVI follow up: deploying virtual assistants

Antihypertensives: more effective at morning or night?

Low Lp(a) levels unlikely to increase the risk of diabetes

» View more highlights on the 2024 ESC Congress hub page

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits